Table 3.
Self-reported adverse events after receiving the first and second dose of any of the available COVID-19 vaccines distributed by Ecuadorian participants characteristics.
| Symptoms | Gender n (%) | Comorbidities n (%) | History of COVID-19 Infection n (%) | Age n (%) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total n | Female | Male | Other | p Value * | No | Yes | p Value * | No | Yes | p Value * | <50 Years | >50 Years | p Value * | ||
| Mild self-reported ESAVIs | 22,814 | Joint pain | 1083 (66.9) | 535 (33.0) | 1 (0.1) | 0.200 | 890 (55.0) | 729 (45.0) | <0.001 | 1151 (71.1) | 468 (28.9) | 0.799 | 1292 (79.2) | 327 (20.2) | <0.001 |
| Headache | 2355 (67.2) | 1143 (32.6) | 4 (0.1) | 0.593 | 2021 (57.7) | 1481 (42.3) | <0.001 | 2565 (73.2) | 937 (26.8) | <0.001 | 2785 (79.5) | 717 (20.5) | <0.001 | ||
| Muscle pain | 1865 (64.4) | 1028 (35.5) | 4 (0.1) | <0.001 | 1683 (58.1) | 1214 (41.9) | <0.001 | 2086 (72.0) | 811 (28.0) | 0.708 | 2308 (79.7) | 589 (20.3) | <0.001 | ||
| Pain or swelling at the injection site | 2969 (66.0) | 1528 (34.0) | 3 (0.1) | 0.045 | 2570 (57.1) | 1930 (42.9) | <0.001 | 3337 (74.2) | 1,163 (25.8) | <0.001 | 3609 (80.2) | 891 (19.8) | <0.001 | ||
| Fatigue or tiredness | 2209 (66.9) | 1088 (32.9) | 5 (0.2) | 0.192 | 1931 (58.5) | 1371 (41.5) | <0.001 | 2480 (75.1) | 822 (24.9) | 0.056 | 2739 (82.9) | 563 (17.1) | <0.001 | ||
| Shaking chills | 1375 (65.5) | 723 (34.4) | 2 (0.1) | 0.071 | 1302 (62.0) | 798 (38.0) | <0.001 | 1506 (71.7) | 594 (28.3) | 0.582 | 1760 (83.8) | 340 (16.2) | <0.001 | ||
| Mild/low grade fever (37.1–38 °C) | 941 (64.1) | 527 (35.9) | 1 (0.1) | 0.385 | 889 (60.5) | 580 (39.5) | <0.001 | 1005 (68.4) | 464 (31.6) | 0.374 | 1245 (84.8) | 224 (15.2) | <0.001 | ||
| General Discomfort | 1801 (64.5) | 988 (35.4) | 5 (0.2) | 0.691 | 1692 (60.6) | 1,102 (39.4) | <0.001 | 2005 (71.8) | 789 (28.2) | 0.283 | 2300 (82.3) | 494 (17.7) | <0.001 | ||
| Gastrointestinal Discomfort | 367 (69.4) | 162 (30.6) | 0 (0.0) | 0.328 | 286 (54.1) | 243 (45.9) | <0.001 | 405 (76.6) | 124 (23.4) | 0.023 | 419 (79.2) | 110 (20.8) | 0.075 | ||
| Urinary Discomfort | 71 (69.6) | 31 (30.4) | 0 (0.0) | 0.288 | 67 (65.7) | 35 (34.3) | 0.086 | 68 (66.7) | 34 (33.3) | 0.225 | 85 (83.3) | 17 (16.7) | 0.297 | ||
| Moderate self-reported ESAVIs | 2987 | Diarrhea | 287 (71.0) | 117 (29.0) | 0 (0.0) | 1 | 213 (52.7) | 191 (47.3) | < 0.001 | 305 (75.5) | 99 (24.5) | 0.004 | 308 (76.2) | 96 (23.8) | 0.004 |
| Skin rash | 116 (73.0) | 43 (27.0) | 0 (0.0) | 0.776 | 82 (51.6) | 77 (48.4) | 0.0166 | 119 (74.8) | 40 (25.2) | 0.019 | 124 (78.0) | 35 (22.0) | <0.001 | ||
| Fever (>38 °C) | 536 (64.7) | 291 (35.1) | 2 (0.2) | 0.857 | 523 (63.1) | 306 (36.9) | <0.001 | 578 (69.7) | 251 (30.3) | 0.006 | 686 (82.8) | 143 (17.2) | <0.001 | ||
| Swollen Glands | 315 (74.3) | 108 (25.5) | 1 (0.2) | 0.048 | 235 (55.4) | 189 (44.6) | <0.001 | 308 (72.6) | 116 (27.4) | 0.844 | 351 (82.8) | 73 (17.2) | 0.045 | ||
| Nausea | 564 (77.2) | 166 (22.7) | 1 (0.1) | 0.389 | 406 (55.5) | 325 (44.5) | <0.001 | 545 (74.6) | 186 (25.4) | 0.843 | 606 (82.9) | 125 (17.1) | 0.544 | ||
| Pruritus (Itching) | 239 (79.4) | 62 (20.6) | 0 (0.0) | 0.833 | 158 (52.5) | 143 (47.5) | 0.019 | 206 (68.4) | 95 (31.6) | 1 | 249 (82.7) | 52 (17.3) | <0.001 | ||
| Vomit | 110 (79.1) | 29 (20.9) | 0 (0.0) | 0.808 | 75 (54.0) | 64 (46.0) | <0.001 | 99 (71.2) | 40 (28.8) | 0.022 | 115 (82.7) | 24 (17.3) | 0.056 | ||
| Severe self-reported ESAVIs | 434 | Anaphylaxis | 4 (44.4) | 5 (55.6) | 0 (0.0) | 1 | 5 (55.6) | 4 (44.4) | 0.906 | 5 (55.6) | 4 (44.4) | 0.906 | 8 (88.9) | 1 (11.1) | 0.495 |
| Tachycardia | 191 (74.3) | 66 (25.7) | 0 (0.0) | 0.830 | 112 (43.6) | 145 (56.4) | 0.003 | 189 (73.5) | 68 (26.5) | 0.702 | 193 (75.1) | 64 (24.9) | 0.398 | ||
| Guillain Barre sd. | 4 (40.0) | 6 (60.0) | 0 (0.0) | 1 | 9 (90.0) | 1 (10.0) | 1 | 9 (90.0) | 1 (10.0) | 1 | 8 (80.0) | 2 (20.0) | 1 | ||
| Facial swelling | 17 (65.4) | 9 (34.6) | 0 (0.0) | 1 | 12 (46.2) | 14 (53.8) | 0.254 | 18 (69.2) | 8 (30.8) | 1 | 18 (69.2) | 8 (30.8) | 0.279 | ||
| High Blood Pressure | 62 (71.3) | 25 (28.7) | 0 (0.0) | 0.227 | 21 (24.1) | 66 (75.9) | 0.002 | 66 (75.9) | 21 (24.1) | 0.529 | 50 (57.5) | 37 (42.5) | 0.922 | ||
| Transverse Myelitis | 1 (50.0) | 1 (50.0) | 0 (0.0) | N/D | 1 (50.0) | 1 (50.0) | N/D | 1 (50.0) | 1 (50.0) | #N/D | 2 (100.0) | 0 (0.0) | N/D | ||
| Facial Paralysis | 7 (63.6) | 4 (36.4) | 0 (0.0) | 0.206 | 6 (54.5) | 5 (45.5) | 0.206 | 8 (72.7) | 3 (27.3) | 1 | 8 (72.7) | 3 (27.3) | 0.513 | ||
| Coagulation Disorders | 18 (56.3) | 14 (43.8) | 0 (0.0) | 0.355 | 17 (53.1) | 15 (46.9) | 1 | 17 (53.1) | 15 (46.9) | 1 | 26 (81.3) | 6 (18.8) | 0.039 | ||
| Total | 17,507 (66.7) | 8699 (33.2) | 29 (0.1) | 15,206 (58.0) | 11,029 (42.0) | 19,081 (72.7) | 7154 (27.3) | 21,294 (81.2) | 4917 (18.8) | ||||||
Table 3 shows the frequency distribution of ESAVIs; the numbers in parentheses show the row percentages for each variable (gender, comorbidities, history of COVID-19 infection, and age group). * The p-value was obtained by Chi-Square test.